Inventor · disambiguated record
Con Panousis
Also filed as: PANOUSIS CON
18 granted patents·23 pending applications·113 citations·filing 2002–2024
93Inventor score
Files withCSL LTD20CSL BEHRING GMBH4LUDWIG INST FOR CANCER RES LTD4LUDWIG INST CANCER RES3PANOUSIS CON3
Top patents by PatentIndex Score
41 records- 0195US7589180B2Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 15, 2009·70 cites·4 claims
- 0290US9856326B2Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodiesCSL BEHRING GMBH·Filed 2016·Granted Jan 2, 2018·9 cites·23 claims
- 0388US9856325B2Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodiesCSL BEHRING GMBH·Filed 2016·Granted Jan 2, 2018·6 cites·24 claims
- 0486US2025051462A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2024·Application pending·0 cites
- 0585US11840573B2CD131 binding proteins and uses thereofCSL LTD·Filed 2020·Granted Dec 12, 2023·1 cites·20 claims
- 0685US9758585B2Compositions and methods for targeting type 1 interferon producing cellsCSL LTD·Filed 2015·Granted Sep 12, 2017·2 cites·16 claims
- 0785US9518127B2Inhibitory anti-factor XII/XIIA monoclonal antibodies and their usesPANOUSIS CON·Filed 2012·Granted Dec 13, 2016·8 cites·22 claims
- 0884US2024117073A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 0982US9193793B2Antibodies against G-CSFR and uses thereofNASH ANDREW DONALD·Filed 2012·Granted Nov 24, 2015·6 cites·21 claims
- 1081US8569461B2Humanized anti-interleukin 3 receptor alpha chain antibodiesPANOUSIS CON·Filed 2011·Granted Oct 29, 2013·5 cites·4 claims
- 1179US10047161B2Humanized anti-interleukin 3 receptor alpha chain antibodiesCSL LTD·Filed 2015·Granted Aug 14, 2018·2 cites·4 claims
- 1277US2024174757A1Cd131 binding proteins and uses thereofCSL LTD·Filed 2023·Application pending·0 cites
- 1376US10513560B2Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodiesCSL BEHRING GMBH·Filed 2017·Granted Dec 24, 2019·1 cites·21 claims
- 1473US11174321B2Method of treating atherosclerosisCSL LTD·Filed 2017·Granted Nov 16, 2021·1 cites·13 claims
- 1573US10806774B2Mutated truncated von Willebrand FactorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·42 claims
- 1671US12071484B2Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded proteinCSL LTD·Filed 2020·Granted Aug 27, 2024·0 cites·14 claims
- 1771US2021032366A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 1870US10808023B2Mutated von Willebrand factorCSL Behring Lengnau AG·Filed 2017·Granted Oct 20, 2020·1 cites·22 claims
- 1967US11345759B2Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodiesCSL BEHRING GMBH·Filed 2019·Granted May 31, 2022·0 cites·22 claims
- 2065US2022089778A1Coagulation factor binding proteins and uses thereofCSL LTD·Filed 2021·Application pending·0 cites
- 2164US2009220510A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2008·Application pending·0 cites
- 2263US2023086472A1Human serum albumin variants and uses thereofCSL LTD·Filed 2022·Application pending·0 cites
- 2363US2019055313A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2018·Application pending·0 cites
- 2461US2018057606A1Methods of treating meningiomaLUDWIG INST FOR CANCER RES LTD·Filed 2017·Application pending·0 cites
- 2561US2022017638A1Method of treating atherosclerosisCSL LTD·Filed 2021·Application pending·0 cites
- 2660US2025171536A1Methods of Bone Marrow ConditioningCSL Innovation Pty Ltd·Filed 2023·Application pending·0 cites
- 2759US2017226214A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2017·Application pending·0 cites
- 2859US2021292411A1Method of treating cancerCSL LTD·Filed 2020·Application pending·0 cites
- 2956US2014086912A1Humanized anti-interleukin 3 receptor alpha chain antibodiesCSL LTD·Filed 2013·Application pending·0 cites
- 3055US2016031998A1Antibodies against g-csfr and uses thereofCSL LTD·Filed 2015·Application pending·0 cites
- 3155US2016046726A1Specific binding proteins and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2015·Application pending·0 cites
- 3254US2016376364A1Method of treating cancerCSL LTD·Filed 2014·Application pending·0 cites
- 3352US11466073B2Human serum albumin variants and uses thereofCSL LTD·Filed 2018·Granted Oct 11, 2022·0 cites·6 claims
- 3451US2019248920A1Coagulation factor binding proteins and uses thereofCSL LTD·Filed 2017·Application pending·0 cites
- 3547US2019023783A1Method of treating cancerCSL LTD·Filed 2018·Application pending·0 cites
- 3646US2022332804A1Complement C2 Binding Proteins and Uses ThereofCSL Innovation Pty Ltd·Filed 2020·Application pending·0 cites
- 3745US9617329B2Method of cloning nucleic acidPANOUSIS CON·Filed 2011·Granted Apr 11, 2017·0 cites·21 claims
- 3843US2022273713A1Method of inhibiting or activating gamma delta t cellsUNIV MELBOURNE·Filed 2020·Application pending·0 cites
- 3939US11505619B2Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney diseaseCSL LTD·Filed 2018·Granted Nov 22, 2022·0 cites·17 claims
- 4037US2011076232A1Specific binding proteins and uses thereofLUDWIG INST CANCER RES·Filed 2010·Application pending·0 cites
- 4132US2019119377A1Recombinant igg fc multimersCSL BEHRING RECOMBINANT FACILITY AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Con Panousis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →